Common name in Nepal: Liraglutide (Victoza, Saxenda), Semaglutide injectable (Ozempic) and oral (Rybelsus), Dulaglutide (Trulicity) — availability and cost vary; these are newer, higher-cost injectable (mostly) medications compared with the other classes in this series.
GLP-1 receptor agonists ("GLP-1 RAs") are a newer class of injectable (and, in one case, oral) medications for type 2 diabetes that mimic the body's own gut incretin hormone, GLP-1. They differ from DPP-4 inhibitors — which merely protect the body's own GLP-1 from breakdown — by directly and more powerfully activating the GLP-1 receptor. This class has become widely known both for diabetes control and for substantial weight loss, and several agents in the class now carry separate approvals for obesity treatment.
GLP-1 receptor agonists bind directly to GLP-1 receptors found on pancreatic beta cells, the brain, the stomach, and the cardiovascular system. On the pancreas, this stimulates insulin release only when blood sugar is elevated (glucose-dependent), and suppresses glucagon release from alpha cells, reducing the liver's glucose output. In the stomach, these drugs slow gastric emptying, which flattens the after-meal glucose rise and contributes to early fullness. In the brain (hypothalamus), they reduce appetite and food intake, which is the main driver of the weight loss seen with this class. Because insulin release only happens when glucose is already high, GLP-1 RAs carry a low risk of hypoglycemia on their own.
GLP-1 receptor agonists are among the most effective glucose-lowering agents available, often reducing HbA1c by 1 to 1.8 percentage points depending on the specific drug and dose. They also produce meaningful weight loss — ranging from around 5% of body weight with liraglutide to considerably more with higher-dose semaglutide — an effect most other diabetes drugs do not share. Several agents in this class have also demonstrated reductions in major cardiovascular events (heart attack, stroke, cardiovascular death) in patients with existing cardiovascular risk, along with modest kidney-protective effects such as reduced protein leakage in the urine.
Gastrointestinal effects are by far the most common — nausea, vomiting, diarrhea, constipation, and abdominal pain, especially when starting treatment or increasing the dose. These are directly related to the drug's effect of slowing gastric emptying and are usually reduced by starting at a low dose and increasing gradually over weeks.
Gallbladder disease — gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) occur more often with GLP-1 RAs than with placebo, likely related to rapid weight loss and changes in gallbladder motility. Patients should be told to report right-upper-abdomen pain, especially after fatty meals.
Pancreatitis — acute pancreatitis has been reported with this class, though large studies and regulatory reviews have generally not confirmed a clear excess risk beyond what is seen in diabetes itself. Persistent, severe abdominal pain (often radiating to the back) warrants urgent medical attention regardless.
Thyroid C-cell tumors (theoretical/animal-based risk) — in rodent studies, some GLP-1 RAs caused thyroid C-cell tumors, including medullary thyroid carcinoma; this has not been confirmed in humans over the available follow-up period, but as a precaution these drugs are generally avoided in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Other reported effects include injection-site reactions, a small increase in heart rate, worsening of existing diabetic retinopathy (eye disease) if blood sugar drops very quickly after starting, and — because of delayed stomach emptying — an increased risk of food/fluid aspiration under general anesthesia, which is why some anesthesia guidelines recommend holding these drugs before elective surgery.
GLP-1 receptor agonists should generally be avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and used cautiously (or avoided) in people with a history of pancreatitis or significant gallbladder disease. People with pre-existing diabetic retinopathy should have their eyes checked before starting, since rapid glucose improvement can transiently worsen retinopathy. Patients should be told to stop eating well before feeling full to avoid nausea and vomiting, and to inform their surgical/anesthesia team that they are on this medication before any procedure requiring sedation, since it may need to be paused beforehand.
Before starting, it is reasonable to ask about personal or family history of medullary thyroid carcinoma/MEN2, gallbladder disease, and pancreatitis, and to check baseline weight and, where relevant, a retinal (eye) examination if retinopathy is a concern. During treatment, HbA1c is typically checked every 3 to 6 months, weight and gastrointestinal tolerance are monitored at follow-up visits, and kidney function may be checked periodically given the modest renal effects of this class. There is no routine requirement for thyroid ultrasound or calcitonin screening in average-risk patients, but any new neck lump or hoarseness should prompt evaluation.
Nauck MA, Quast DR, Wefers J, Meier JJ. "GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art." Molecular Metabolism, 2021.
Smits MM, Van Raalte DH. "Safety of Semaglutide." Frontiers in Endocrinology, 2021.
He L, et al. "Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases." JAMA Internal Medicine, 2022.
Bezin J, et al. "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer." Diabetes Care, 2023.
American Society of Anesthesiologists consensus guidance on perioperative management of GLP-1 receptor agonists.
This article has been published by the Healthnep editorial team for general information and educational purposes only. The author is not a licensed medical doctor or professional healthcare practitioner. The content provided here does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified health provider regarding any medical condition or before starting any new treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this platform.
Common name in Nepal (Glimepiride, Gliclazide, and Glipizide)What Are Sulfonylureas?Sulfon...
Read MoreWhat Are SGLT2 Inhibitors?SGLT2 इनहिबिटर के हो?SGLT2 inhibitors ar...
Read More